TY - JOUR T1 - Apolipoprotein E genotype, lifestyle and coronary artery disease: gene-environment interaction analyses in the UK Biobank population JF - medRxiv DO - 10.1101/2020.01.29.20019620 SP - 2020.01.29.20019620 AU - Maxime M Bos AU - Lina de Vries AU - Patrick CN Rensen AU - Ko Willems van Dijk AU - Gerard Jan Blauw AU - Diana van Heemst AU - Raymond Noordam Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/02/03/2020.01.29.20019620.abstract N2 - Background Carriers of the APOE ε4 genotype have an increased risk for developing coronary artery disease (CAD), but there is preliminary evidence that lifestyle factors interact with APOE genotype on CAD risk. Here, we assessed the interactions of physical activity, oily fish intake and polyunsaturated fatty acid (PUFA) intake with APOE genotype on risk of incident cardiovascular disease in a large population of middle-aged individuals.Methods and Results The present study was embedded in the UK Biobank population and comprised 344,092 European participants (mean age: 56.5 years, 45.7% men) without a history of CAD. Information regarding physical activity, oily fish intake and PUFA intake was collected through questionnaires, and information on incident CAD through linkage with hospital admission records. Analyses were performed using Cox proportional hazard models adjusted for age and sex. From these analyses, higher physical activity level and a higher intake of oily fish were associated with a lower incidence of CAD. These associations were similar across all APOE isoform groups (p-values for interaction > 0.05). A higher PUFA intake was only associated with a lower CAD risk in APOE ε4 carriers (hazard ratio: 0.76, 95% confidence interval: 0.62,0.90), however, no statistically significant interaction was observed (p-valueinteraction = 0.137).Conclusion While higher physical activity, fish intake and PUFA intake all decreased the risk of CAD, no evidence for interaction of these lifestyle factors with APOE genotype was observed in UK Biobank participants. Interventions intended to reduce cardiovascular risk might therefore be similarly effective across the APOE isoform carriers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe present UK Biobank project was conducted under project number 32292. Statistical analyses were performed using the facilities of the Dutch Super computer (Surfsara, Inc; access granted by the Dutch Research Council to RN). DvH was supported by the European Commission funded project HUMAN (Health-2013-INNOVATION-1-602757).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData of the UK Biobank is available upon acceptance of a research proposal. https://www.ukbiobank.ac.uk/ ER -